# Salbutamol hfa-134a PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/salbutamol-hfa-134a

> Salbutamol hfa-134a, sponsored by GSK plc (GSK): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | salbutamol hfa-134a |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Asthma](https://sec-api.dev/indications/asthma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." https://clinicaltrials.gov/study/NCT06261957

### October 6, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." https://clinicaltrials.gov/study/NCT06261957?tab=results

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/salbutamol-hfa-134a.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Salbutamol hfa-134a PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/salbutamol-hfa-134a

```bibtex
@misc{secapidev_pdufa_salbutamol_hfa_134a_20261116,
  title        = {Salbutamol hfa-134a PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/salbutamol-hfa-134a}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_salbutamol_hfa_134a_20261116","title":"Salbutamol hfa-134a PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/salbutamol-hfa-134a","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
